On November 13, the National Medical Insurance Administration held a discussion in Beijing on strengthening the application of medical insurance supervision of drug traceability codes. The Health Bureau found at the scene that relevant leaders of the drug supervision department also attended. The heads of more than 40 leading companies such as Fosun Pharma, Jiuzhoutong, China Resources Pharmaceutical, Meituan Buy Medicine, Yixintang, and Yifeng Pharmacy attended the meeting.

At the meeting, Gu Rong, Director of the Fund Supervision Department of the National Medical Insurance Administration, pointed out that "the medical insurance department's strengthening of drug traceability code supervision is not only a major measure to safeguard the safety and legitimate rights and interests of the majority of insured persons, but also a major measure to support the high-quality development of enterprises. At the same time, it can also help enterprises prevent products from being counterfeited, crack down on the black industry of drug reselling, and safeguard the legitimate rights and interests of enterprises."

He hopes that the pharmaceutical companies and the medical insurance departments will move in the same direction, strengthen self-discipline and self-warning, conduct self-inspection and self-correction in a timely manner, improve the traceability management system, cooperate with the medical insurance departments to carry out collection and supervision and verification, give full play to the role of whistleblowers in combating fraud and insurance fraud, and jointly protect the "medical money" and "life-saving money" of the people. After the drug traceability code system is improved, if it is found that the company is still engaged in illegal activities, it will be severely investigated and resolutely exposed.

The National Medical Insurance Bureau is considering adding a traceability code to the drug shopping receipt. Ordinary consumers can scan the code on their mobile phones to query the drug sales record. If it is found that the drug has multiple swipe records, they can report it directly to the medical insurance department.

At present, the National Medical Insurance Bureau is developing a big data supervision model for "scalping medical insurance drugs" and strengthening the intelligent reminder function of the monitoring system. The National Medical Insurance Bureau especially reminds: as long as the medical insurance return drugs enter the secondary circulation, even if they are no longer swiped for medical insurance, they will violate other laws and regulations on drug supervision.

Flying inspections, interviews, tracing back, big data monitoring, mass reporting... The National Medical Insurance Bureau has prepared a variety of means to strike hard against the unhealthy ecology in the field of drug circulation.

https://mp.weixin.qq.com/